BACKGROUND: Mastocytosis is characterized by the accumulation of aberrant mast cells (MC). Patients suffering from mastocytosis suffer from a wide range of symptoms due to increased levels of MC mediators. It would therefore be of great benefit to inhibit MC mediator release. However, to date there are few drugs available that are known to effectively lower MC mediator levels. The evidence for the involvement of the janus kinase 2 (JAK2)-signal transducer and activation of transcription 5 (STAT5) signalling pathway in MC activation is slowly accumulating. Interference with the JAK2-STAT5 pathway might inhibit MC mediator release. Ruxolitinib, a JAK1/JAK2 inhibitor, indeed decreases symptoms like pruritus and fatigue in patients with myeloproliferative neoplasms. Yet, detailed studies on how ruxolitinib affects human mast cell activity are lacking. OBJECTIVE: To investigate the effect of JAK1/2-inhibition with ruxolitinib in the human mast cell lines LAD2 and HMC1. METHODS: LAD2 and HMC1 were stimulated with substance P, codeine or the calcium ionophore A23817. The effect of ruxolitinib on mast cell degranulation (via measurement of β-hexosaminidase, histamine release and CD63 membrane expression) and IL-6, IL-13, MCP-1 and TNF-α production was investigated. The involvement of STAT5 activation was explored using the selective STAT5 inhibitor pimozide. RESULTS: Ruxolitinib effectively inhibited codeine- and substance P-induced degranulation in a concentration-dependent manner. Ruxolitinib also significantly inhibited the production of IL-6, TNF-α and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation. This renders the JAK-STAT pathway as an interesting target for therapy to release symptom burden in mastocytosis and many other MC mediator-related diseases.
BACKGROUND:Mastocytosis is characterized by the accumulation of aberrant mast cells (MC). Patients suffering from mastocytosis suffer from a wide range of symptoms due to increased levels of MC mediators. It would therefore be of great benefit to inhibit MC mediator release. However, to date there are few drugs available that are known to effectively lower MC mediator levels. The evidence for the involvement of the janus kinase 2 (JAK2)-signal transducer and activation of transcription 5 (STAT5) signalling pathway in MC activation is slowly accumulating. Interference with the JAK2-STAT5 pathway might inhibit MC mediator release. Ruxolitinib, a JAK1/JAK2 inhibitor, indeed decreases symptoms like pruritus and fatigue in patients with myeloproliferative neoplasms. Yet, detailed studies on how ruxolitinib affects human mast cell activity are lacking. OBJECTIVE: To investigate the effect of JAK1/2-inhibition with ruxolitinib in the human mast cell lines LAD2 and HMC1. METHODS: LAD2 and HMC1 were stimulated with substance P, codeine or the calcium ionophore A23817. The effect of ruxolitinib on mast cell degranulation (via measurement of β-hexosaminidase, histamine release and CD63 membrane expression) and IL-6, IL-13, MCP-1 and TNF-α production was investigated. The involvement of STAT5 activation was explored using the selective STAT5 inhibitor pimozide. RESULTS:Ruxolitinib effectively inhibited codeine- and substance P-induced degranulation in a concentration-dependent manner. Ruxolitinib also significantly inhibited the production of IL-6, TNF-α and MCP-1 as induced by A23817 and substance P. Selective STAT5 inhibition with pimozide resulted in diminished degranulation and inhibition of cytokine production as induced by A23817 and substance P. CONCLUSIONS & CLINICAL RELEVANCE: This study demonstrates that the JAK1/JAK2 inhibitor ruxolitinib can inhibit MCactivity, possibly through prevention of STAT5 activation. This renders the JAK-STAT pathway as an interesting target for therapy to release symptom burden in mastocytosis and many other MC mediator-related diseases.
Authors: Leonard B Weinstock; Arthur S Walters; Jill B Brook; Zahid Kaleem; Lawrence B Afrin; Gerhard J Molderings Journal: J Clin Sleep Med Date: 2020-01-14 Impact factor: 4.062
Authors: Alba Pérez-Pons; María Jara-Acevedo; Ana Henriques; Paula Navarro-Navarro; Andrés C García-Montero; Iván Álvarez-Twose; Carlos E Pedreira; Laura Sánchez-Muñoz; Daniela Damasceno; Carolina Caldas; Javier I Muñoz-González; Almudena Matito; Juan Flores-Montero; Oscar González-López; Ignacio Criado; Andrea Mayado; Alberto Orfao Journal: Clin Transl Allergy Date: 2022-06-14 Impact factor: 5.657
Authors: Jacob Pfeil; Lauren M Sanders; Ioannis Anastopoulos; A Geoffrey Lyle; Alana S Weinstein; Yuanqing Xue; Andrew Blair; Holly C Beale; Alex Lee; Stanley G Leung; Phuong T Dinh; Avanthi Tayi Shah; Marcus R Breese; W Patrick Devine; Isabel Bjork; Sofie R Salama; E Alejandro Sweet-Cordero; David Haussler; Olena Morozova Vaske Journal: PLoS Comput Biol Date: 2020-04-10 Impact factor: 4.475
Authors: Maud A W Hermans; Astrid C van Stigt; Sanne van de Meerendonk; Benjamin Schrijver; Paul L A van Daele; Petrus M van Hagen; Marloes van Splunter; Willem A Dik Journal: Front Immunol Date: 2021-03-15 Impact factor: 7.561
Authors: Eddy H C Wang; Isha Monga; Brigitte N Sallee; James C Chen; Alexa R Abdelaziz; Rolando Perez-Lorenzo; Lindsey A Bordone; Angela M Christiano Journal: PNAS Nexus Date: 2022-07-11